Regeneron Pharmaceuticals anticipates a $56 million pre-tax acquired in-process research and development (IPR&D) charge for Q3 2024. This charge, related to development milestone and up-front payments for collaboration and licensing agreements, is expected to impact both GAAP and non-GAAP net income per diluted share by approximately $0.43.The company notes that IPR&D charges may include acquisitions, up-front payments, opt-in fees, development milestones, and premiums on equity securities related to collaborations. Regeneron does not forecast these charges due to their unpredictable nature. The Q3 2024 results are preliminary and subject to finalization.Regeneron emphasizes that this information is not "filed" for Securities Exchange Act purposes and should not be considered incorporated by reference in any Securities Act filings unless explicitly stated. The company also cautions that actual results may differ from these estimates and includes a note on the use of non-GAAP financial measures in its reporting.

Regeneron Pharmaceuticals anticipates a $56 million pre-tax acquired in-process research and development (IPR&D) charge for Q3 2024. This charge, related to development milestone and up-front payments for collaboration and licensing agreements, is expected to impact both GAAP and non-GAAP net income per diluted share by approximately $0.43.The company notes that IPR&D charges may include acquisitions, up-front payments, opt-in fees, development milestones, and premiums on equity securities related to collaborations. Regeneron does not forecast these charges due to their unpredictable nature. The Q3 2024 results are preliminary and subject to finalization.Regeneron emphasizes that this information is not "filed" for Securities Exchange Act purposes and should not be considered incorporated by reference in any Securities Act filings unless explicitly stated. The company also cautions that actual results may differ from these estimates and includes a note on the use of non-GAAP financial measures in its reporting.